ArticleJournal of circulating biomarkers
Diagnostic value of carcinoembryonic antigen, cancer antigen 15-3, and cell-free DNA as blood biomarkers in early detection of canine mammary tumor.
Article in Journal of circulating biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026Review
- AKR1B1 promotes canine mammary tumorigenesis via activation of PI3K/AKT signaling and acts as a serum biomarker.Scientific reports · 2026Article
- Erratum in "Diagnostic value of carcinoembryonic antigen, cancer antigen 15-3, and cell-free DNA as blood biomarkers in early detection of canine mammary tumor".Journal of circulating biomarkersArticle
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Blood biomarkers play a crucial role in the diagnosis and prognosis of tumor. The present research was designed to study the diagnostic effect of serum biomarkers, namely carcino-embryonic antigen (CEA), cancer antigen 15-3 (CA15-3), and plasma biomarker Methods: A total of 60 blood samples were collected. Out of which 36 samples were from the dogs affected with canine mammary tumors, and 24 samples were from the apparently healthy dogs. CEA and CA15-3 were estimated using Sandwich ELISA, and cfDNA was estimated by the ccfDNA kit. A significant Positive correlation was observed between tumor blood biomarker levels, cytology and histopathological grades of the tumors. Results: We found that CA15-3 can be a more effective serum tumour biomarker than CEA for diagnosing canine mammary gland tumours. This finding showed a positive correlation with the clinical grade of the disease. The concentration of serum markers and cfDNA in animals affected with malignant mammary gland tumours was higher compared to the benign entity of tumours and healthy control groups. The ROC curve analysis revealed that the sensitivity (Se) and specificity (Sp) of CEA and CA15-3 biomarkers improved when used together. IN comparison to healthy controls, canines with both benign and malignant neoplasia showed significantly higher (p < 0.05) cfDNA concentrations. Conclusion: This study highlights the role of blood tumor biomarkers for routine screening of animals in early diagnosis of tumors, further treatment, and prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.